Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Humana (HUM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Humana: Leadership In Medicare Advantage Underpins Recession-Resilient Value.

Humana: Leadership In Medicare Advantage Underpins Recession-Resilient Value

Humana Inc. (HUM) Q1 2023 Earnings Call Transcript.

Humana Inc. (HUM) Q1 2023 Earnings Call Transcript

Humana (HUM) expects adjusted EPS to be at least $28.25 in 2023, up from the previous guidance of $28 per share.

Humana (HUM) Q1 Earnings Beat on Growing Membership & Premiums

Humana Inc. HUM, the healthcare company that specializes in Medicare insurance, said Wednesday it had net income of $1.614 billion, or $9.87 a share, in the first quarter, up from $1.220 billion, or $7.29 a share, in the year-earlier period. Adjusted per-share earnings came to $9.38, ahead of the $9.27 FactSet consensus.

Humana posts stronger-than-expected Q1 earnings and raises guidance

Humana Inc raised its annual adjusted profit forecast on Wednesday after lower medical costs in the firm's government-backed health insurance business helped it beat profit estimates for the first quarter.

Insurer Humana lifts profit view as medical costs drop in govt plans

4 Reasons I Am Considering Adding Humana To My Portfolio.

4 Reasons I Am Considering Adding Humana To My Portfolio

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and net earnings per share (EPS) for the quarter ended March 31, 2023 (1Q23) versus the quarter ended March 31, 2022 (1Q22) as noted in the tables below. Consolidated income before income taxes and equity in net earnings (pretax results) In millions 1Q23 (a) 1Q22 (b) Generally Accepted Accounting Principles (GAAP) $1,614   $1,220   Amortization associated with identifiable intangibles 18   19  .

Humana Reports First Quarter 2023 Financial Results; Raises Full Year 2023 Financial Guidance

Agilon Health

Cano Health

Viatris

Growing patient volumes, admissions, health awareness and technological improvement in the first quarter are likely to have aided healthcare players like Humana (HUM), Viatris (VTRS), agilon health (AGL) and Cano Health (CANO).

4 Healthcare Stocks Poised to Beat Q1 Earnings Estimates

Assetmark Financial Holdings Inc

ICF International

Marcus

Riley Exploration Permian

The crux of safe investment lies in choosing a company that is not burdened with debt as a debt-free stock is almost impossible to find. You may buy MCS, AMK, HUM, REPX and ICFI.

Buy These 5 Low Leverage Stocks Ahead of Big Earnings Releases

Gilead Sciences

Johnson & Johnson

Moderna

Pfizer

UnitedHealth Group

The United States healthcare system includes two sectors: public endeavors like Medicare and Medicaid and private health insurance companies. Healthcare stocks represent a significant section of the U.S. economy, with many medical companies included in indexes like the S&P 500.

6 Best Healthcare Stocks to Buy Right Now

Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Humana (HUM) This Earnings Season?

Humana's (HUM) first-quarter results are likely to reflect surging premiums and investment income.

Will Humana's (HUM) Q1 Earnings Beat on Insurance Unit Strength?

Domino's Pizza

Humana and Domino's Pizza each have solid growth prospects. The two companies pay well-covered and growing dividends.

Expecting a Tax Refund? Here Are 2 Remarkable Dividend Growth Stocks to Consider

Latest round of funding raises Humana's total financial commitment for affordable housing to $90 million, increases scope of national program to include additional communities.

Humana Announces Additional $40 Million Investment in Affordable Housing

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Bulls Look Optimistic About Humana (HUM): Should You Buy?

The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM), is investing $1 million to bolster mental health resources in its hometown of Louisville, Ky., following the aftermath of Monday's mass shooting in downtown Louisville.

Humana Foundation Invests $1 Million to Support Louisville in Wake of Shootings

Does Humana (HUM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Humana (HUM) Is Up 7.11% in One Week: What You Should Know

PHILADELPHIA , April 10, 2023 /PRNewswire/ -- Humana (NYSE: HUM) and Thomas Jefferson University proudly announce the selection of Billy Oglesby, PhD, as the Humana Dean of the University's College of Population Health (JCPH).

Billy Oglesby, PhD, Named Humana Dean at Thomas Jefferson University's College of Population Health

Here is how Humana (HUM) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Humana (HUM) This Year?

GameStop

Investors seem to be encouraged by the March jobs report, which reflects a resilient economy and moderate inflation. You may buy MCS, GME, AMK, HUM & ICFI.

Buy These 5 Low Leverage Stocks as U.S. Releases Job Report

CSL Ltd

Horizon Pharma

Novo Nordisk

The top and bottom-line growth make these Zacks Medical stocks very attractive.

5 Diverse Medical Stocks to Buy for 2023 and Beyond

Humana (HUM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Humana (HUM) Upgraded to Buy: Here's What You Should Know

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), one of the nation's leading health and well-being companies, released its 2022 Impact Report, which highlights the company's continued commitment to its Environmental, Social and Governance (ESG) strategy.

Humana's Impact Report Focuses on Transforming Care and Positive Health Outcomes for All

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

News for Humana Stock (HUM)